Cargando…
Cases with Refractory Ascites and a Delayed Response to Tolvaptan
The patient was a 67-year-old female with liver cirrhosis due to hepatitis C. She was administered furosemide at 20 mg/day and spironolactone at 25 mg/day, but the ascites did not improve. Despite the additional administration of tolvaptan at 3.75 mg/day, the response to ascites was still poor. Whil...
Autores principales: | Hagiwara, Satoru, Nishida, Naoshi, Chishina, Hirokazu, Ida, Hiroshi, Sakurai, Toshiharu, Komeda, Yoriaki, Kitano, Masayuki, Kudo, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173493/ https://www.ncbi.nlm.nih.gov/pubmed/27853068 |
Ejemplares similares
-
Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Hagiwara, Satoru, et al.
Publicado: (2021) -
Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis
por: Hagiwara, Satoru, et al.
Publicado: (2017) -
A case of HCC successfully treated with infliximab‐steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy
por: Hagiwara, Satoru, et al.
Publicado: (2022) -
The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3
por: Sakurai, Toshiharu, et al.
Publicado: (2017) -
Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)